Remicade monotherapy approved for psoriatic arthritis

The monoclonal antibody, Remicade (infliximab) has been approved for use as monotherapy in the treatment of active and progressive psoriatic arthritis that has responded inadequately to disease-modifying anti-rheumatic drugs in patients where methotrexate is contraindicated or not tolerated.

Previously, Remicade was licensed only for use in combination with methotrexate to treat the condition.
The recommended dosage is 5mg/kg by intravenous infusion over a two-hour period, repeated two and six weeks after the first infusion and then every six to eight weeks.

Further information: Schering-Plough Ltd, Schering-Plough House, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW. Tel: (01707) 363636.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...